Additional Information

Description

Nulojix 250 mg Vial is an immunosuppressive agent used for the prevention of organ rejection in adult patients receiving a kidney transplant. It contains belatacept, a selective T-cell co-stimulation blocker that helps suppress the immune system’s response to the transplanted organ. It is administered in combination with other immunosuppressive therapies, including corticosteroids and mycophenolate mofetil, to achieve effective graft protection.

The active ingredient, belatacept, functions by binding to CD80 and CD86 receptors on antigen-presenting cells, thereby preventing the activation of T-cells. This mechanism reduces the immune-mediated attack on the transplanted kidney, lowering the risk of acute rejection.

This medication is specifically indicated for Epstein-Barr virus (EBV)-seropositive kidney transplant recipients due to an increased risk of post-transplant lymphoproliferative disorder (PTLD) in EBV-negative patients. It is used under strict medical supervision to balance immunosuppression while reducing the risk of infection and malignancy.